Skip to content

Meprobamate

Published: July 26, 2026Updated: August 24, 2026

Meprobamate is an anxiolytic (antianxiety) and sedative medication historically used to treat anxiety disorders, tension, and insomnia. It also possesses muscle relaxant properties and was once commonly prescribed for conditions involving muscle spasms. Due to safety concerns including dependence risk and toxicity in overdose, it has largely been replaced by newer medications.

Quick summary

Meprobamate is an older anxiolytic medication used for anxiety and tension, with significant safety concerns that have limited its modern use.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 24, 2026Editorial policy

Key facts at a glance

ATC
N05BC01
RxNorm
6760
Generic
Meprobamate
Class
atc-n05
Brands
Equagesic
Availability
rx
Lactation
unknown
Routes
oral
Forms
tablet
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Dosage and administration

adult (standard)tablet
Usual dose
500mg twice daily
Maximum
consult physician
Frequency
every 12 hours
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
pediatric (standard)tablet
Usual dose
250mg twice daily
Maximum
consult physician
Frequency
every 12 hours
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
geriatric (standard)tablet
Usual dose
400mg daily
Maximum
consult physician
Frequency
once daily
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard

Overdose information

Important overdose information
Toxic dose: Single dose exceeding 10 grams may cause serious toxicity and potentially fatal respiratory depression
Chronic overdose: Prolonged use at high doses may lead to tolerance, dependence, and cumulative CNS depression
Immediate actions
Secure airway and provide respiratory support, consider gastric decontamination with activated charcoal within 1-2 hours of ingestion, establish IV access for fluid resuscitation
Antidote
No specific antidote exists(Treatment is supportive and symptomatic; early intervention improves outcomes)
Poison Control: 1-800-222-1222

Special Populations

10 groups
✗

pregnancy

first trimester
unsafe
FDA Category
D
Dose Adjustment

avoid if possible

Key Recommendations

avoid use during pregnancy unless benefits outweigh risks; meprobamate crosses the placenta

Monitor

regular fetal monitoring and ultrasound assessments

Use of this medication in this population requires careful consideration of risks and benefits.

✗

pregnancy

second trimester
unsafe
FDA Category
D
Dose Adjustment

avoid if possible

Key Recommendations

avoid use during pregnancy; consider alternative therapies

Monitor

regular fetal monitoring

Use of this medication in this population requires careful consideration of risks and benefits.

✗

pregnancy

third trimester
unsafe
FDA Category
D
Dose Adjustment

avoid

Key Recommendations

avoid use near term; may cause neonatal sedation and withdrawal

Monitor

neonatal assessment for withdrawal symptoms and respiratory depression

Use of this medication in this population requires careful consideration of risks and benefits.

✗

lactation

breastfeeding
unsafe
FDA Category
D
Dose Adjustment

contraindicated

Key Recommendations

meprobamate is excreted in breast milk; avoid breastfeeding during treatment

Monitor

not applicable - avoid breastfeeding

Use of this medication in this population requires careful consideration of risks and benefits.

⚠

geriatric

elderly
caution
FDA Category
N
Dose Adjustment

reduce dose by 50%

Key Recommendations

use with caution in elderly due to increased sensitivity to CNS effects; start at lowest effective dose

Monitor

monitor for excessive sedation, confusion, falls, and respiratory depression

Use with caution and monitor for adverse effects.

✗

pediatric_age

children adolescents
unsafe
FDA Category
D
Dose Adjustment

not recommended

Key Recommendations

not recommended for use in children and adolescents; contraindicated in children under 6 years

Monitor

not applicable

Use of this medication in this population requires careful consideration of risks and benefits.

⚠

renal_impairment

mild
caution
FDA Category
N
Dose Adjustment

reduce dose by 25%

Key Recommendations

use with caution; monitor renal function

Monitor

monitor renal function and drug levels if available

Use with caution and monitor for adverse effects.

✗

renal_impairment

severe
unsafe
FDA Category
N
Dose Adjustment

avoid or reduce dose by 50-75%

Key Recommendations

use with extreme caution; consider alternative therapy

Monitor

frequent monitoring of renal function and drug levels

Use of this medication in this population requires careful consideration of risks and benefits.

⚠

hepatic_impairment

mild to moderate
caution
FDA Category
N
Dose Adjustment

reduce dose by 25-50%

Key Recommendations

use with caution due to hepatic metabolism; monitor for excessive sedation

Monitor

monitor liver function tests and clinical response

Use with caution and monitor for adverse effects.

✗

hepatic_impairment

severe
unsafe
FDA Category
N
Dose Adjustment

avoid if possible

Key Recommendations

avoid in severe hepatic impairment due to significantly reduced metabolism

Monitor

not applicable - avoid use

Use of this medication in this population requires careful consideration of risks and benefits.

Statistics and clinical data

prescribingFDA
2023

Commonly prescribed since

Value:1950s

General prescribing information

drug_classWHO
2023

Drug class

Value:Carbamate anxiolytic

Drug class information

usageMedical guidelines
2023

Common uses

Value:Anxiety disorders, muscle tension, sedation

Common therapeutic uses

mechanism pharmacology references
2023

Mechanism of action

Value:GABA-A receptor modulator

Mechanism of action information

Meprobamate was primarily prescribed for generalized anxiety disorder, tension headaches, and insomnia. It also served as a muscle relaxant for conditions involving muscle spasms and was sometimes used for alcohol withdrawal symptoms.

Meprobamate works by modulating GABA-A receptors in the central nervous system, enhancing the inhibitory effects of GABA neurotransmitter. This results in decreased neuronal excitability, producing anxiolytic, sedative, and muscle relaxant effects.

Meprobamate carries a high risk of physical dependence and tolerance with prolonged use. Overdose can be life-threatening, particularly when combined with alcohol or other CNS depressants. Due to these safety concerns, it is rarely prescribed today and has largely been replaced by benzodiazepines and SSRIs for anxiety treatment.

Contraindications

Conditions and patient states where this medication should be avoided or used with caution.

Do not use (1)

ABSOLUTEhypersensitivity

Known allergy to this medication or its components

Use caution (1)

RELATIVEpregnancy

Consult healthcare provider for benefits vs risks assessment

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy